Molecular Genetics of Charcot-marie-tooth Disease: from Genes to Genomes

Overview

Journal Mol Syndromol

Date 2013 Jan 8

PMID 23293578

Citations 24

Authors

H Azzedine

J Senderek

C Rivolta

R Chrast

Affiliations

Soon will be listed here.

Abstract

Charcot-Marie-Tooth disease (CMT) is a heterogeneous group of disorders of the peripheral nervous system, mainly characterized by distal muscle weakness and atrophy leading to motor handicap. With an estimated prevalence of 1 in 2,500, this condition is one of the most commonly inherited neurological disorders. Mutations in more than 30 genes affecting glial and/or neuronal functions have been associated with different forms of CMT leading to a substantial improvement in diagnostics of the disease and in the understanding of implicated pathophysiological mechanisms. However, recent data from systematic genetic screening performed in large cohorts of CMT patients indicated that molecular diagnosis could be established only in ∼50-70% of them, suggesting that additional genes are involved in this disease. In addition to providing an overview of genetic and functional data concerning various CMT forms, this review focuses on recent data generated through the use of highly parallel genetic technologies (SNP chips, sequence capture and next-generation DNA sequencing) in CMT families, and the current and future impact of these technologies on gene discovery and diagnostics of CMTs.

Citing Articles

Clinical and genetic features of CMT2T in Italian patients confirm the importance of MME pathogenic variants in idiopathic, late-onset axonal neuropathies.

Geroldi A, La Barbera A, Mammi A, Origone P, Gaudio A, Ponti C J Peripher Nerv Syst. 2024; 29(4):472-486.

PMID: 39251209 PMC: 11625992. DOI: 10.1111/jns.12657.

Regulation of Endosomal Trafficking by Rab7 and Its Effectors in Neurons: Clues from Charcot-Marie-Tooth 2B Disease.

Mulligan R, Winckler B Biomolecules. 2023; 13(9).

PMID: 37759799 PMC: 10527268. DOI: 10.3390/biom13091399.

A variant of the gene detected in the clinical exome: etiology of a peripheral neuropathy undiagnosed for 20 years.

Lahoz Alonso R, Sienes Bailo P, Capablo Liesa J, de Andres S, Bancalero Flores J, Izquierdo Alvarez S Adv Lab Med. 2023; 1(4):20200033.

PMID: 37360614 PMC: 10197443. DOI: 10.1515/almed-2020-0033.

Dysregulation of organelle membrane contact sites in neurological diseases.

Kim S, Coukos R, Gao F, Krainc D Neuron. 2022; 110(15):2386-2408.

PMID: 35561676 PMC: 9357093. DOI: 10.1016/j.neuron.2022.04.020.

A nonsense mutation in MME gene associates with autosomal recessive late-onset Charcot-Marie-Tooth disease.

Jamiri Z, Khosravi R, Heidari M, Kiani E, Gharechahi J Mol Genet Genomic Med. 2022; 10(5):e1913.

PMID: 35212467 PMC: 9034668. DOI: 10.1002/mgg3.1913.

References

Cuesta A, Pedrola L, Sevilla T, Garcia-Planells J, Chumillas M, Mayordomo F . The gene encoding ganglioside-induced differentiation-associated protein 1 is mutated in axonal Charcot-Marie-Tooth type 4A disease. Nat Genet. 2001; 30(1):22-5. DOI: 10.1038/ng798. View

Tang B, Zhao G, Luo W, Xia K, Cai F, Pan Q . Small heat-shock protein 22 mutated in autosomal dominant Charcot-Marie-Tooth disease type 2L. Hum Genet. 2004; 116(3):222-4. DOI: 10.1007/s00439-004-1218-3. View

Somandin C, Gerber D, Pereira J, Horn M, Suter U . LITAF (SIMPLE) regulates Wallerian degeneration after injury but is not essential for peripheral nerve development and maintenance: implications for Charcot-Marie-Tooth disease. Glia. 2012; 60(10):1518-28. DOI: 10.1002/glia.22371. View

Misko A, Jiang S, Wegorzewska I, Milbrandt J, Baloh R . Mitofusin 2 is necessary for transport of axonal mitochondria and interacts with the Miro/Milton complex. J Neurosci. 2010; 30(12):4232-40. PMC: 2852190. DOI: 10.1523/JNEUROSCI.6248-09.2010. View

dYdewalle C, Krishnan J, Chiheb D, Van Damme P, Irobi J, Kozikowski A . HDAC6 inhibitors reverse axonal loss in a mouse model of mutant HSPB1-induced Charcot-Marie-Tooth disease. Nat Med. 2011; 17(8):968-74. DOI: 10.1038/nm.2396. View

Thomas P, Harding A . Inherited neuropathies: the interface between molecular genetics and pathology. Brain Pathol. 1993; 3(2):129-33. DOI: 10.1111/j.1750-3639.1993.tb00737.x. View

Fabrizi G, Ferrarini M, Cavallaro T, Cabrini I, Cerini R, Bertolasi L . Two novel mutations in dynamin-2 cause axonal Charcot-Marie-Tooth disease. Neurology. 2007; 69(3):291-5. DOI: 10.1212/01.wnl.0000265820.51075.61. View

Spinosa M, Progida C, De Luca A, Colucci A, Alifano P, Bucci C . Functional characterization of Rab7 mutant proteins associated with Charcot-Marie-Tooth type 2B disease. J Neurosci. 2008; 28(7):1640-8. PMC: 6671532. DOI: 10.1523/JNEUROSCI.3677-07.2008. View

Chrast R, Saher G, Nave K, Verheijen M . Lipid metabolism in myelinating glial cells: lessons from human inherited disorders and mouse models. J Lipid Res. 2010; 52(3):419-34. PMC: 3035679. DOI: 10.1194/jlr.R009761. View

10.

Nagarajan R, Svaren J, Le N, Araki T, Watson M, Milbrandt J . EGR2 mutations in inherited neuropathies dominant-negatively inhibit myelin gene expression. Neuron. 2001; 30(2):355-68. DOI: 10.1016/s0896-6273(01)00282-3. View

11.

Hayasaka K, Himoro M, Sato W, Takada G, Uyemura K, Shimizu N . Charcot-Marie-Tooth neuropathy type 1B is associated with mutations of the myelin P0 gene. Nat Genet. 1993; 5(1):31-4. DOI: 10.1038/ng0993-31. View

12.

Lupo V, Galindo M, Martinez-Rubio D, Sevilla T, Vilchez J, Palau F . Missense mutations in the SH3TC2 protein causing Charcot-Marie-Tooth disease type 4C affect its localization in the plasma membrane and endocytic pathway. Hum Mol Genet. 2009; 18(23):4603-14. DOI: 10.1093/hmg/ddp427. View

13.

Marrosu M, Vaccargiu S, Marrosu G, Vannelli A, Cianchetti C, Muntoni F . Charcot-Marie-Tooth disease type 2 associated with mutation of the myelin protein zero gene. Neurology. 1998; 50(5):1397-401. DOI: 10.1212/wnl.50.5.1397. View

14.

Fischer C, Trajanoski S, Papic L, Windpassinger C, Bernert G, Freilinger M . SNP array-based whole genome homozygosity mapping as the first step to a molecular diagnosis in patients with Charcot-Marie-Tooth disease. J Neurol. 2011; 259(3):515-23. PMC: 3296015. DOI: 10.1007/s00415-011-6213-8. View

15.

Bouche P, Gherardi R, CATHALA H, LHERMITTE F, CASTAIGNE P . Peroneal muscular atrophy. Part 1. Clinical and electrophysiological study. J Neurol Sci. 1983; 61(3):389-99. DOI: 10.1016/0022-510x(83)90172-7. View

16.

SANGER F, Coulson A . A rapid method for determining sequences in DNA by primed synthesis with DNA polymerase. J Mol Biol. 1975; 94(3):441-8. DOI: 10.1016/0022-2836(75)90213-2. View

17.

Coppola G, Geschwind D . Genomic medicine enters the neurology clinic. Neurology. 2012; 79(2):112-4. DOI: 10.1212/WNL.0b013e31825f06d9. View

18.

Lupski J, Slaugenhaupt S, Pentao L, Guzzetta V, Trask B, Saucedo-Cardenas O . DNA duplication associated with Charcot-Marie-Tooth disease type 1A. Cell. 1991; 66(2):219-32. DOI: 10.1016/0092-8674(91)90613-4. View

19.

Mastaglia F, Nowak K, Stell R, Phillips B, Edmondston J, Dorosz S . Novel mutation in the myelin protein zero gene in a family with intermediate hereditary motor and sensory neuropathy. J Neurol Neurosurg Psychiatry. 1999; 67(2):174-9. PMC: 1736462. DOI: 10.1136/jnnp.67.2.174. View

20.

Seburn K, Nangle L, Cox G, Schimmel P, Burgess R . An active dominant mutation of glycyl-tRNA synthetase causes neuropathy in a Charcot-Marie-Tooth 2D mouse model. Neuron. 2006; 51(6):715-26. DOI: 10.1016/j.neuron.2006.08.027. View